Lixte director receives 40,000 RSUs grant

Sawyer Jason David reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Sawyer Jason David reported acquisition or exercise transactions in this Form 4 filing.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Jason David Sawyer received an equity award of 40,000 restricted stock units (RSUs). The grant was made under the company’s 2020 Stock Incentive Plan after performance conditions in his RSU agreement were satisfied. Following this award, he holds 65,000 RSUs, all of which have vested.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Sawyer Jason David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 65,000 shares (Direct)

Footnotes (2)

1. F1. The reported transaction involved the Reporting Person's receipt of 40,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 40,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.
2. F2. The total reported in Column 5 includes (i) the 40,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

Key Figures

RSUs granted: 40,000 RSUs Total RSUs held after grant: 65,000 RSUs Grant price per RSU: $0.00 per unit

3 metrics

RSUs granted 40,000 RSUs Equity award to director on 2026-07-01

Total RSUs held after grant 65,000 RSUs All reported as vested following award

Grant price per RSU $0.00 per unit Compensation grant, not open-market purchase

Key Terms

restricted share units ("RSUs"), 2020 Stock Incentive Plan, performance conditions

3 terms

restricted share units ("RSUs") financial

"The reported transaction involved the Reporting Person's receipt of 40,000 restricted share units ("RSUs")."

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."

performance conditions financial

"The 40,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LIXT director Jason David Sawyer report?

Jason David Sawyer reported receiving an award of 40,000 restricted stock units (RSUs). These RSUs were granted as equity compensation under Lixte Biotechnology’s 2020 Stock Incentive Plan after specified performance conditions in his RSU agreement were met.

How many LIXT restricted stock units does Jason David Sawyer now hold?

After the reported grant, Jason David Sawyer holds a total of 65,000 RSUs. This total includes 40,000 newly awarded RSUs and 25,000 previously granted RSUs, with all of these units reported as having vested under their terms.

Was cash paid for the 40,000 LIXT RSUs granted to Jason David Sawyer?

No cash was paid for the 40,000 RSUs, which were granted at a price of $0.00 per unit. They represent equity compensation rather than an open‑market share purchase, contingent on previously satisfied performance conditions and continued service.

What plan governs Jason David Sawyer’s new LIXT RSU award?

The 40,000 RSUs were granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. The award is subject to the applicable RSU agreement, including performance conditions and a requirement for continued service to receive underlying common shares.

Are Jason David Sawyer’s LIXT RSUs currently vested?

The filing states that the 40,000 newly awarded RSUs vested upon achievement of performance conditions in the RSU agreement, which have been satisfied. It further notes that the 25,000 previously reported RSUs have also vested, so all 65,000 RSUs are vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawyer Jason David

(Last) (First) (Middle)

433 PLAZA REAL.,

SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		40,000(1)	A	$0	65,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of 40,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 40,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

2. The total reported in Column 5 includes (i) the 40,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

	/s/ Jason Sawyer	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)